Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Biocon chief Kiran...

    Biocon chief Kiran Shaw vows to cut cost of rh-Insulin

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-29T10:00:06+05:30  |  Updated On 29 Sept 2019 10:00 AM IST
    Biocon chief Kiran Shaw vows to cut cost of rh-Insulin

    New Delhi: Biocon Chief, Kiran Mazumdar-Shaw, Philanthropist and Founder of Biocon, recently, announced her personal commitment towards enabling universal access to high-quality insulin by offering recombinant human Insulin (rh-Insulin) at less than 10 US cents/day in low and middle-income countries (LMICs). These countries, which form most of the world, contribute to 80% of the global disease burden.


    The announcement was made at the United Nations General Assembly (UNGA) side meeting on innovation and universal health access convened by UNAIDS Health Innovation Exchange, in the presence of the President of Ethiopia, the First Lady of Namibia, Health Ministers from Botswana and Malawi, and representatives from the Private Sector and Development Agencies. The forum on 'Accelerating Innovations and Investments for Access to Healthcare' was co-sponsored by UNAIDS and the Center for Global Health and Development.


    Biocon Biologics’ recombinant human insulin has been developed using the scientific expertise and world-class R&D and manufacturing facilities that have allowed it to bring multiple biosimilar medicines to the US and Europe. The Company is committed to use its science, scale and expertise to shift the access paradigm for patients in need of insulins. Biocon is a global insulins player with over 15 years of experience in addressing the needs of patients with diabetes, have provided over 2 billion doses of human insulin worldwide, thus far.


    Also Read: Biocon subsidiary acquires Chennai-based biological research facility from Pfizer Healthcare


    The announcement by Kiran Mazumdar-Shaw is guided by her conviction that a life-enabling product like insulin cannot be priced out of the reach of those that need it on an everyday basis, whether in the United States or in Africa.


    Biocon’s Recombinant Human insulin offer of less than 10 US cents/day in LMICs is for vials sourced by the government directly from Biocon, assuming an insulin dosage of 40 IU per day.


    Currently, the blended median patient prices in LMICs are US$ 9** per 10 ml vial translating to 36 US cents/ day. The current US list price in retail is over US$ 5*** / day.


    Biocon, an India-based global biopharmaceuticals company is committed to affordability and access and will work with healthcare systems and payers worldwide to ensure that Insulin pricing is not a constraint to the well-being of individuals and of communities.


    She also called upon insulin delivery devices manufacturers to join the movement towards ensuring affordable access to insulins by ensuring lower prices for the insulin pens and needles required to administer the drug.


    Biocon Biologics is willing to work with governments to ensure ways to overcome price barriers, including through special pricing and setting up low-cost manufacturing facilities via public-private partnerships in order to address the huge cost burden borne by people with diabetes.


    In high-income regions like the US, Biocon believes it can make a dramatic impact on the current insulin pricing crisis if its ongoing discussions with the regulators allow the Company to scientifically bridge its clinical data to US reference product. This will reduce clinical development costs and bring the product years earlier to patients who cannot afford insulin therapy.


    Also Read: Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru

    Bioconbiopharmaceuticals companydiabetesinsulineinsuline pricekiranKiran Mazumdar ShawLMICsMITpharmapharma newspharma news indiaphilanthropistRecombinant Human insulinrhinsulineUNGAUnited Nations General AssemblyUS Pharmacopeial ConventionUSIBC

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok